Accueil du site > Revue de presse > Sources d’information > Médical > AIDSMeds.com
AIDSMeds.com
http://www.aidsmeds.com/news/TopStories.htm
Fil d’information de Reuters Health (en anglais) sur l’actualité thérapeutique du VIH.
-
Telaprevir for Hep C Study Open to People Living With HIV
A clinical trial exploring the safety and effectiveness of Vertex Pharmaceutical's hepatitis C virus (HCV) protease inhibitor telaprevir in people also infected with HIV is open and enrolling patients, according to Vertex-verified report posted online by the National AIDS Treatment Advocacy (...)
-
No Benefit From Cyclosporine During Early Infection
Adding cyclosporine to an antiretroviral (ARV) regimen during the first few weeks or months of HIV infection does not offer additional benefit in terms of virus suppression, CD4 cell increases or reduced immune activation. That's the verdict, according to a study published March 17 in The (...)
-
Twice-Daily ARV Treatment Better than Once-Daily for Some
Even though people living with HIV may be more likely to adhere to a Kaletra (lopinavir/ritonavir)-based treatment regimen taken once a day compared with twice a day, those with high pre-treatment viral loads may experience virologic failure faster using Kaletra's once-daily dosing option, (...)
-
Chemical in Bananas May Prevent and Treat HIV
A chemical in bananas has been found to inhibit HIV, according to research findings from a University of Michigan Medical School published in the March 19 issue of the Journal of Biological Chemistry. According to the study authors, this may lead to the development of inexpensive microbicides (...)
-
Sexual Problems More Common Among HIV-Positive Women
Women living with HIV are significantly more likely to experience sexual problems compared with those not living with the virus, according to new results from the Women's Interagency HIV Study (WIHS) published online ahead of print by the Journal of Acquired Immune Deficiency Syndromes (...)
-
Replication Capacity: An Additional Measure of HIV Disease Progression?
HIV's replication capacity (RC), a measurement of the virus's fitness, may be useful for people living with HIV and their health care providers in figuring out how quickly HIV disease will progress, according to new data published in the April 1 issue of the Journal of Acquired Immune (...)
-
Treatment Interruptions “Particularly Hazardous” for Those Coinfected With Hep B
Interrupting antiretroviral (ARV) therapy may be “particularly hazardous” for people living with HIV and chronic hepatitis B virus (HBV) infection, according to data from the Strategies for the Management of Antiretroviral Therapy (SMART) study published online by the journal AIDS. Increases in (...)
-
HIV and the Brain: Part 2
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco—David Evans speaks with Scott Letendre, MD, from the University of California in San Diego, about the relationship of HIV levels in the brain versus the blood, and what that might mean for treating (...)
-
New Treatments for HIV: Part 1
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco—Tim Horn speaks with David Hardy, MD, from Cedars Sinai Medical Center in Los Angeles, about new HIV treatments—including the drug blood level-booster, cobicistat, and the new integrase inhibitor, (...)
-
New Treatments for HIV: Part 2
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco—Tim Horn speaks with David Hardy, MD, from Cedars Sinai Medical Center in Los Angeles, about new HIV treatments—including two entry inhibitors: vicriviroc and TBR-652. Part 2 of a 2-part (...)